GSC
GEVA

Ground Swell Capital’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Ground Swell Capital’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1K Sell
15
-85
-85% -$6.09K ﹤0.01% 2336
2014
Q2 		$10K Buy
+100
New +$8.51K 0.02% 754

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Ground Swell Capital's GEVA Position: Q3 2014 in Review

Ground Swell Capital reduced its SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) stake by 85% in Q3 2014, selling an estimated $6.09K and leaving 15 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2336.

Ground Swell Capital first reported a position in GEVA in Q2 2014 and has held it in 2 quarters since. The position peaked at $10K in Q2 2014. 120 funds tracked by Wall St. Rank hold GEVA as of Q3 2014.

  • Ground Swell Capital held 15 shares of SYNAGEVA BIOPHARMA CORP COM STK (DE) worth $1K as of Q3 2014.
  • Ground Swell Capital sold 85 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q3 2014, an estimated $6.09K.
  • SYNAGEVA BIOPHARMA CORP COM STK (DE) made up ﹤0.01% of Ground Swell Capital's portfolio in Q3 2014, its #2336 holding.
  • Ground Swell Capital first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2014 and has held it in 2 quarters since.
  • Ground Swell Capital's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $10K in Q2 2014.
  • 120 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.